Cannabinoid receptor 1 ligands revisited: Pharmacological assessment in the ACTOne system.

Analytical Biochemistry
Chaela S PresleyBob M Moore

Abstract

In vitro cannabinoid pharmacology has evolved over time from simple receptor binding to include [(35)S]GTPγ, β-arrestin, and cAMP assays. Each assay has benefits and drawbacks; however, no single functional system has been used for high-throughput evaluation of compounds from binding to pharmacological functionality and antagonist assessment in a well-characterized human cell line. In this study, we evaluated and validated one system-ACTOne human embryonic kidney cells transfected with a cyclic nucleotide gated channel and cannabinoid receptor 1 (CB1)-and compared human CB1 affinity, functional, and antagonistic effects on cAMP with previously published results. The study was conducted on a diverse group of CB1 ligands, including endocannabinoids and related compounds, 2-AG, AEA, MAEA, and ACEA, the phytocannabinoid Δ(9) THC, and synthetic cannabinoids CP 55,940, WIN 55,212-2, SR 141716A, CP 945,598, and WIN 55,212-3. Our results were compared with literature values where human CB1 was used for affinity determination and cAMP was used as a functional readout. Here we report the first detailed evaluation of the ACTOne assay for the pharmacological evaluation of CB1 ligands. The results from the study reveal some interesting devi...Continue Reading

References

Oct 1, 1991·The Biochemical Journal·C M GérardM Parmentier
Mar 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·M HerkenhamK C Rice
Jun 10, 1994·Journal of Medicinal Chemistry·V AbadjiA Makriyannis
Aug 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·C C FelderW A Devane
Oct 25, 1996·Journal of Medicinal Chemistry·A D KhanolkarA Makriyannis
Aug 5, 1998·British Journal of Pharmacology·S J MacLennanD W Bonhaus
Aug 28, 1999·Bioorganic & Medicinal Chemistry Letters·M KanyonyoD M Lambert
Mar 22, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·T Kenakin
Jun 8, 2002·Prostaglandins, Leukotrienes, and Essential Fatty Acids·R G Pertwee, R A Ross
Jul 12, 2002·Biochemical Pharmacology·Sean D McAllisterMary E Abood
Sep 25, 2002·Chemistry and Physics of Lipids·Carol A RouzerLawrence J Marnett
Dec 31, 2002·Chemistry and Physics of Lipids·Thien P DinhDaniele Piomelli
May 31, 2003·Canadian Journal of Physiology and Pharmacology·Clemente VásquezLeonardo Hernández
May 25, 2004·British Journal of Pharmacology·Theodore J PriceChristopher M Flores
Oct 19, 2004·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Sophie J GovaertsDidier M Lambert
Nov 11, 2005·Journal of Medicinal Chemistry·Antonella BrizziVincenzo Di Marzo
Nov 18, 2005·The New England Journal of Medicine·Jean-Pierre DesprésUNKNOWN Rimonabant in Obesity-Lipids Study Group
Feb 16, 2006·JAMA : the Journal of the American Medical Association·F Xavier Pi-SunyerUNKNOWN RIO-North America Study Group
Mar 30, 2006·International Journal of Obesity : Journal of the International Association for the Study of Obesity·R G Pertwee
Mar 31, 2006·Journal of Medicinal Chemistry·Giovanni AppendinoVincenzo Di Marzo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.